# A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

Study · id `cardio:ct-nct07664553` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07664553](<https://clinicaltrials.gov/study/NCT07664553>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07664553

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07664553. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2028-05-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07664553, source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)
- Started: 2026-07-08 (actual) (ClinicalTrials.gov record NCT07664553, source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)
- Primary completion: 2028-05-23 (anticipated) (ClinicalTrials.gov record NCT07664553, source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)
- Completion: 2028-05-23 (anticipated) (ClinicalTrials.gov record NCT07664553, source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)
- Countries: United States; Australia; Bulgaria; Canada; China; Czechia; Germany; India; Japan; Malaysia; Poland; South Korea; Thailand (ClinicalTrials.gov record NCT07664553, source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07664553-2026-08-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
- Acronym: Eluminate-3
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 79a580c9e31a413947d81246d3fa290a648efbd3d908621da80b09cfad9564c4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
